Answers are grounded in this paper and cite their sources.
Rituximab, the monoclonal antibody against B lymphocyte protein CD20, is a major asset for treatment of diseases in which B CD20 cells are the foremost etiologic culprit. Based on observations that rituximab is capable to modulate immune responses the question if the drug may affect the capacity of human peripheral blood mononuclear cells (PBMC) for cytokine production was posed.
No takes yet. Share an insight, caveat, or question.
Meir-Djaldetti et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: